August 30, 2025 a 11:43 am
LLY: Fundamental Ratio Analysis - Eli Lilly and Company
Eli Lilly and Company operates in the healthcare industry, primarily focusing on the discovery, development, and marketing of pharmaceuticals worldwide. Currently, the company holds a strong position with a stable financial background. With a wide array of products targeting various diseases, it shows promise for long-term growth.
Fundamental Rating
Based on our analysis, Eli Lilly maintains a decent overall score amidst strong performance metrics in Return on Equity and Return on Assets.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
Historical ratings indicate a slight improvement in the overall score, reflecting stability over time.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-08-29 | 3 | 4 | 5 | 5 | 1 | 1 | 1 |
| No Date | 0 | 4 | 5 | 5 | 1 | 1 | 1 |
Analysts' Price Targets
Analysts have set a broad range for the target price with a median value that reflects moderate optimism regarding future stock performance.
| High | Low | Median | Consensus |
|---|---|---|---|
| $1146 | $700 | $770 | $856 |
Analysts' Sentiment
The sentiment around Eli Lilly's stock is generally positive, with a majority favoring a 'Buy' recommendation.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 32 | |
| Hold | 8 | |
| Sell | 2 | |
| Strong Sell | 0 |
Conclusion
Eli Lilly and Company shows a balanced financial profile with strong potential for continued growth in the pharmaceutical industry. Despite its solid scores in ROE and ROA, the company faces challenges with its debt-to-equity ratio and valuation metrics. With a broad product range and strategic collaborations, Eli Lilly remains a key player in the healthcare sector, but potential investors should consider market dynamics and industry risks.